The experiment is over. This week's signals show AI moving into the infrastructure layer — in pharma operations, in regulatory review, and in the ambitions of every communications firm that works with them.
BMS signs enterprise AI deal covering 30,000 employees
Bristol Myers Squibb has signed an enterprise agreement giving all 30,000+ employees access to Claude across R&D, medical affairs, regulatory, and manufacturing. The company's CTO frames this not as deploying a chatbot but as building a shared intelligence platform — specifically, unlocking value trapped in data silos. This is the clearest signal yet that major pharmaceutical companies are treating AI as infrastructure rather than experiment. For health communications professionals, the question is no longer whether your clients are using AI. It's whether your outputs are built to work alongside it.
FDA is now using AI to parse submissions — your documents have two audiences
Regulatory submissions must now satisfy algorithmic reviewers as well as human ones. Metis Consulting sets out a dual-audience framework: structure your documents for both a machine parsing for patterns and a human expert reading for judgement. The risk matrix they offer — model influence × decision consequence — is a practical tool for calibrating how much you need to worry about any given submission type. The implication for medical writers is direct: document architecture is now a regulatory competency, not just a preference.
Ten AI capabilities set to redefine medical communications in 2026
Envision Pharma has published a forward-looking list of AI applications they see reshaping the field. The most interesting are the ones that compress time: real-time congress intelligence (competitive landscape analysis within hours of presentations), personalised field briefings, and an integrated medical affairs operating model that treats all AI functions as a single system rather than separate tools. Worth reading less as a prediction and more as a map of what vendors are already building towards — and therefore what clients will soon expect.
HCPs still turn to trusted sources when it matters
Despite AI proliferation, healthcare professionals continue to reach for peer-reviewed journals, specialist colleagues, and professional bodies when making clinical decisions. The MM+M data is a useful corrective to the assumption that AI is displacing traditional trust hierarchies in medicine — it is not, at least not yet. For communicators, this is a reminder that credibility still flows from evidence and expertise, not from technological novelty. Build on the foundations that HCPs already trust.
AI EVALUATORS DRIFT WITH CONVERSATION MOOD — YOUR REVIEW PIPELINE IS COMPROMISED
If your team is using LLMs to batch-review promotional copy, clinical summaries, or MLR-prep outputs in a single conversation thread, stop and read this. Prior items in a session are silently skewing scores — negative content amplifies downstream negativity, and the model is rationalising rather than evaluating. The fix isn’t complex, but it requires acknowledging that your current process has a systematic flaw you probably haven’t stress-tested for.
GOOGLE BURIES SOURCE LINKS as AI Mode Kills Referral Traffic
Clickthrough rates from Google AI Overviews to external sites are down 58%. That number applies to everything: medical publisher content, KOL-authored pieces, agency white papers, congress abstracts. The clinicians and payers your materials are written for are increasingly receiving an AI-synthesised answer instead of reaching your carefully crafted source. Distribution strategy built around Google search rankings needs a rethink, now.
AI PURGE: SaaS Firm Cuts 22% of Staff, Promises Survivors Million-Dollar Salaries
ClickUp is a tech company, not a health communications agency — but the logic it’s applying is arriving here regardless. Fewer generalists, dramatically higher pay for people who can direct AI systems at scale, and no public apology for the arithmetic. Senior people in agencies and pharma medical affairs teams should be asking whether their current headcount models assume AI is a productivity multiplier or a partial replacement. Those are meaningfully different bets.
SALESFORCE LOCKS IN MARGINS; CUSTOMERS WILL PAY FOR AI WHETHER THEY LIKE IT
Pharma commercial and medical affairs teams running Salesforce or Veeva-adjacent stacks: AI feature costs are being baked into enterprise renewals, and Gartner is already flagging the renegotiation risk. The headline is about SaaS broadly, but the mechanism — captive enterprise customers absorbing AI pricing they didn’t specifically choose — is the same one playing out across every major vendor category you use.
COMPLIANCE FICTION: AI Audit Snapshots Fail EU AI Act’s Continuous Oversight Demand
Point-in-time validation — run a benchmark, pass, done — is not what EU AI Act compliance actually requires for ongoing deployments. Regulatory bodies are moving toward continuous behavioural monitoring, and anyone running LLMs in MLR or regulatory writing workflows who has built their compliance case on a one-off audit needs to revisit the architecture. This paper maps exactly where current practice falls short of what the regulation demands.That's it for this edition. Back Friday.
— Ned